Cynata Therapeutics Limited (CYP.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 03:49PM AEDT
| Previous close | 0.3450 |
| Open | 0.3450 |
| Bid | 0.3400 x 1582700 |
| Ask | 0.3550 x 3535900 |
| Day's range | 0.3370 - 0.3450 |
| 52-week range | 0.2800 - 0.4800 |
| Volume | |
| Avg. volume | 40,249 |
| Market cap | 49.431M |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0280 |
| Earnings date | 23 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
We Think Shareholders Are Less Likely To Approve A Pay Rise For Cynata Therapeutics Limited's (ASX:CYP) CEO For Now
The underwhelming share price performance of Cynata Therapeutics Limited ( ASX:CYP ) in the past three years would have...
- PR Newswire
LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.
© 2023 Yahoo. All rights reserved.
